Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety, tolerability, and efficacy of Peginterferon beta-1a (BIIB017) in pediatric participants with relapsing-remitting m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Plegridy (Peginterferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: ACTIVE_NOT_RECRUITING